An open-label trial of aripiprazole treatment in dual diagnosis individuals: Safety and efficacy

Aimee L. McRae-Clark, Marcia L. Verduin, Bryan K. Tolliver, Rickey E. Carter, Amy E. Wahlquist, Kathleen T. Brady, Jeffrey S. Cluver, Samantha Anderson

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

This open-label study evaluated the safety and efficacy of aripiprazole in the treatment of 20 patients with co-morbid schizophrenia, schizoaffective disorder, or bipolar disorder and alcohol, cocaine, and/or marijuana use disorders. Primary outcomes were substance use, measured by the Timeline Followback, and score on the Clinical Global Impression scale for psychiatric and substance use symptoms. The data suggest that aripiprazole may reduce substance use and improve psychiatric symptoms in patients with co-morbid disorders; however, limitations are noted. Subsequent randomized studies are needed to further explore these findings.

Original languageEnglish (US)
Pages (from-to)83-96
Number of pages14
JournalJournal of Dual Diagnosis
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2009

Keywords

  • Alcohol
  • Aripiprazole
  • Cocaine
  • Dual diagnosis
  • Marijuana

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'An open-label trial of aripiprazole treatment in dual diagnosis individuals: Safety and efficacy'. Together they form a unique fingerprint.

  • Cite this

    McRae-Clark, A. L., Verduin, M. L., Tolliver, B. K., Carter, R. E., Wahlquist, A. E., Brady, K. T., Cluver, J. S., & Anderson, S. (2009). An open-label trial of aripiprazole treatment in dual diagnosis individuals: Safety and efficacy. Journal of Dual Diagnosis, 5(1), 83-96. https://doi.org/10.1080/15504260802620210